Consumer medicine information

Trecondi

Treosulfan

BRAND INFORMATION

Brand name

Trecondi

Active ingredient

Treosulfan

Schedule

SUMMARY CMI

TRECONDI^®

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

▼ This medicine is new or being used differently. Please report side effects. See the full CMI for further details.

1. Why am I using TRECONDI?

Trecondi is used as a treatment before blood stem cell transplantation

in adults with blood cancers called acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS),
in adolescents and children older than one month with cancer found in the blood or bone marrow and non-cancerous disorders.

For more information, see Section 1. Why am I using TRECONDI? in the full CMI.

2. What should I know before I use TRECONDI?

Do not use if you have ever had an allergic reaction to treosulfan.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use TRECONDI? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with TRECONDI and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use TRECONDI?

This medicine is used in combination with other chemotherapeutic agents. Your dose will be calculated by your doctor.
This medicine will be given to you by your doctor or a nurse. It is given by drip (infusion) into a vein over 2 hours for 3 days before blood stem cell infusion.

More instructions can be found in Section 4. How do I use TRECONDI? in the full CMI.

5. What should I know while using TRECONDI?

Things you should do	Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription Undertake regular blood tests during treatment to check your blood cell counts do not fall too low.
Things you should not do	You must not get pregnant during treatment with this medicine and up to 6 months after treatment. Use an effective method of contraception when either you or your partner is receiving this medicine. You should not father a child during and up to 6 months after treatment. You must not receive live vaccines during treatment with treosulfan.
Driving or using machines	This medicine can cause nausea, vomiting and dizziness which may reduce your ability to drive or use machines. If you are affected, do not drive or use machines.
Drinking alcohol	Talk to your doctor about the risks associated with drinking alcohol before and after your treatment.
Looking after your medicine	This medication is cytotoxic and appropriate precautions must be taken when handling treosulfan. For this reason, your medicine will be handled and stored by trained personnel at the hospital.

For more information, see Section 5. What should I know while using TRECONDI? in the full CMI.

6. Are there any side effects?

Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of the common side effects are: infection; allergic reactions; sleeping problems; headache; dizziness; abnormalities in heart rhythm; high or low blood pressure; flushing; difficulty breathing; bleeding from the nose; sore red mouth; diarrhoea; nausea; vomiting; pain; upset stomach; constipation; difficulty swallowing; rash; itchy skin; hair loss; muscle weakness; kidney damage; blood in the urine; tiredness; retention of fluid in the body causing swelling; abnormal laboratory results. If you experience a fever, chest pain, bleeding or sudden weight gain consult your doctor immediately.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.

FULL CMI

TRECONDI^®

Active ingredient: treosulfan

Consumer Medicine Information (CMI)

This leaflet provides important information about using TRECONDI. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using TRECONDI.

Where to find information in this leaflet:

1. Why am I using TRECONDI?
2. What should I know before I use TRECONDI?
3. What if I am taking other medicines?
4. How do I use TRECONDI?
5. What should I know while using TRECONDI?
6. Are there any side effects?
7. Product details

1. Why am I using TRECONDI?

TRECONDI contains the active ingredient treosulfan. TRECONDI belongs to a group of medicines called alkylating agents.

TRECONDI is used as a treatment before blood stem cell transplantation in adults with blood cancers called acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS), and in adolescents and children older than one month with cancer found in the blood or bone marrow and non-cancerous disorders.

2. What should I know before I use TRECONDI?

Warnings

Do not use TRECONDI if:

you are allergic to treosulfan,
if you suffer from an active uncontrolled infection,
if your heart, lung, liver or kidneys are not working properly
if you suffer from hereditary DNA repair disorder, a condition that reduces the ability to repair DNA (which carries your genetic information),
if you are pregnant, think you may be pregnant or are breastfeeding.

Check with your doctor if you:

have any other medical conditions
take any medicines for any other condition

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

TRECONDI may increase the risk of having another cancer in the future. You will have regular follow up with your doctor after treatment with TRECONDI is completed.

TRECONDI may cause symptoms of the menopause (absence of menstrual periods).

Vaccines

You must not receive live vaccines during treatment with treosulfan.

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

You must not get pregnant during treatment with this medicine and up to 6 months after treatment. Use an effective method of contraception when either you or your partner is receiving this medicine.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you receive this medicine.

You should stop breast-feeding before starting treatment with this medicine and not breastfeed for at least 6 months after treatment.

If you are a man treated with this medicine, you should not father a child during and up to 6 months after treatment.

This medicine may make you infertile and it may not be possible for you to get pregnant after treatment with it. If you are concerned about having children, you should discuss this with your doctor before treatment. Men should seek advice about the possibility of sperm preservation before starting therapy.

Children and adolescents

Fits (seizures or convulsions) may occur very rarely in infants of less than 4 months of age. Children younger than 1 year may have more severe side effects that affect breathing. Your child will be monitored for signs of side effects affecting nerves and breathing problems.

Nappy rash with ulceration of the area around the anus (perianal) may occur in infants, toddlers and children wearing nappies because treosulfan passed out in the urine can damage the skin. Therefore, nappies should be changed frequently during 6–8 hours after each dose of this medicine. Skin should be kept clean and dry on days of treosulfan infusion to avoid rash or similar skin reactions.

There is not sufficient information on the use of treosulfan in children aged less than 1 month.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with TRECONDI and affect how it works.

TRECONDI may interfere with some medicines and affect how they work.

Digoxin, a medicine used for treatment of heart failure

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect TRECONDI.

4. How do I use TRECONDI?

How much to use

This medicine is used in combination with other chemotherapeutic agents. Your dose will be calculated by your doctor based on your body size (height and weight).

Your treatment with TRECONDI will be continuously supervised by an experienced doctor in a hospital or in a specialised centre for stem cell transplantation.

How TRECONDI is given

This medicine will be given to you by your doctor. It is given by drip (infusion) into a vein over 2 hours for 3 days before blood stem cell infusion.

If you forget to use TRECONDI

As you will be given this medicine by a doctor or a nurse it is unlikely that a dose will be missed. You must not be given a double dose to make up for a missed dose.

If you use too much TRECONDI

This medicine is given by a doctor or nurse. However, if you think you have received more of this medicine than you should, tell your doctor or nurse as soon as possible.

5. What should I know while using TRECONDI?

Things you should do

TRECONDI is a cell-killing (cytotoxic) medicine that is used to decrease the number of blood cells. At the recommended dose, this is the desired effect. You will have regular blood tests during treatment to check your blood cell counts do not fall too low.

Your doctor will monitor your blood liver enzymes regularly to check your liver is working normally.

In order to prevent and treat infections, you will be given medicines, such as antibiotics, antifungals or antivirals.

Since inflammation of the lining of the mouth is a common side effect of this medicine, you should pay attention to adequate oral hygiene. Preventative use of mouthwashes (e.g. with barrier protectants, antibacterial agents) or application of ice to the lining of the mouth (lessens blood flow to the lining of the mouth and reduces the amount of treosulfan reaching the healthy skin) is recommended.

Call your doctor straight away if you:

experience a fever (high temperature) while using TRECONDI

Remind any doctor, dentist, pharmacist or nurse you visit that you are using TRECONDI.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how TRECONDI affects you.

TRECONDI can cause nausea, vomiting and dizziness which may reduce your ability to drive or use machines. If you are affected, do not drive or use machines.

Drinking alcohol

Tell your doctor if you drink alcohol.

Your doctor will explain the risks associated with drinking alcohol before and after your treatment.

Looking after your medicine

This medication is cytotoxic and appropriate precautions must be taken when handling treosulfan. For this reason, your medicine will be handled and stored by trained personnel at the hospital.

TRECONDI is stored below 25°C.

Keep it where young children cannot reach it.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Your doctor will perform regular blood tests and other observations to check for blood counts, high sugar (glucose) levels in the blood, changes in the body's ability to manage sugar (glucose), unusual amount of acid in the blood (acidosis /alkalosis), unusual amount of salts in the body, increased liver enzymes, increased C-reactive protein (a marker of inflammation in the body) and increased blood level of bilirubin. Your doctor will also check for signs of a second, unrelated cancer.

Less serious side effects	What to do
Allergic reaction: itchy, bumpy rash Metabolism and nutrition related decreased appetite Mental health related problems sleeping (insomnia) confusion agitation Nervous system related headache, dizziness numbness or weakness in the arms and legs (peripheral sensory neuropathy) restless, repetitive, or involuntary movements and rapid speech (extrapyramidal disorder) fainting tingling or numbness in the hands and feet (paresthesia) Eye related dry eye bleeding in the eye (in children) Ear related feeling of spinning or whirling (vertigo) Heart related changes and abnormalities in heart rhythm (heartbeat is irregular, too fast or too slow) breathlessness due to build up of fluids around the lungs or heart Relating to blood vessels dizziness, lightheadedness or headaches due to high or low blood pressure flushing bruising Lung and airway related bleeding from the nose coughing inflammation or pain the throat and mouth hiccups changes in voice	Speak to your doctor if you have any of these less serious side effects and they worry you.
Gastrointestinal related sore red mouth diarrhoea nausea vomiting belly (abdominal) or throat pain mouth or gums pain upset stomach constipation difficulty in swallowing bleeding in the mouth dry mouth feeling bloated Related to the liver liver pain Related to the skin a type of rash with flat or raised red bumps on the skin (maculopapular rash) red spots on the skin (purpura) redness of skin (erythema) palms of the hands or soles of the feet tingle, become numb, painfully swollen, or red (hand and foot syndrome) reddening and flaking of most of the skin of the body (dermatitis exfoliative in children) itching hair loss red spots which start of the limbs and may blister or progress to form raised, red, pale-centered marks, associated with sore throat, fever, headache and/or diarrhoea (erythema multiforme) rash /dermatitis hives (in children) spots that look like acne excessive sweating dry skin skin ulcers or blisters bronze pigmentation of the skin skin pain (in children) death of skin tissue redness of skin covered by diaper, including scrotal skin (in children) Related to muscles and connective tissues pain in arms or legs back pain bone pain joint pain muscle pain muscle weakness pain in the penis (in children)	Speak to your doctor if you have any of these less serious side effects and they worry you.
Related to the kidneys pain and/or increased frequency of urination (cystitis) pain when passing urine pain of the urinary tract General disorders and infusion site conditions tiredness swelling of the hands, feet or ankles due to retention of fluid in the body (oedema) fever chills chest pain (not related to the heart) pain pain, redness or swelling at the site of injection feeling cold Laboratory investigations or observations weight gain weight loss	Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effects

What to do

Allergic reaction

difficulty breathing
swelling of the face, lips, tongue or throat

Infection related

increased susceptibility to infection
fever, chills, confusion or disorientation, difficulty breathing, pain or restlessness due to bloodstream infections (sepsis)

Nervous system related

headache and fever, progressing to hallucinations, confusion, paralysis of part or all of the body, disturbances in behavior, speech and eye movements, stiff neck, and sensitivity to light (encephalopathy)
Sudden weakness, tingling or paralysis of the face, arm or leg, confusion, dizziness, and changes in vision due to bleeding in the brain
seizure (in children)

Heart related

pressure, pain or tightness in the chest or arms, shortness of breath, cold sweat, sudden lightheadedness or dizziness (heart attack)

Speak to your doctor straight away if you notice any of these serious side effects.

Relating to blood vessels

bleeding
swelling, redness, tenderness and a sensation of heat in one arm or leg due to a blood clot

Related to the liver

yellowing of the skin

Lung and airway related

difficulty breathing, wheezing

Gastrointestinal related

blood in vomit or stool, or vomit that looks like coffee grounds (gastrointestinal bleeding)

Related to the kidneys

passing little or no urine associated with drowsiness, nausea, vomiting and breathlessness (acute kidney injury)
blood in the urine

Speak to your doctor straight away if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What TRECONDI contains

Active ingredient (main ingredient)	Treosulfan
Other ingredients (inactive ingredients)	None

Do not take this medicine if you are allergic to any of these ingredients.

What TRECONDI looks like

TRECONDI is a white crystalline powder in a glass vial with a rubber stopper and aluminium cap.

TRECONDI is available in a vial containing 1 g or 5 g of treosulfan powder for injection for infusion. TRECONDI is available in packs containing 1 or 5 vials (type I glass).

TRECONDI 1 g AUST R 369770.

TRECONDI 5 g AUST R 369771.

Who distributes TRECONDI

Link Medical Product Pty Ltd
5 Apollo Street
Warriewood NSW 2012
AUSTRALIA

Ph: 1800 181 060
linkhealthcare.com.au

This leaflet was prepared in September 2022.

Published by MIMS November 2022

BRAND INFORMATION

Brand name

Trecondi

Active ingredient

Treosulfan

Schedule

1 Name of Medicine

Treosulfan.

2 Qualitative and Quantitative Composition

Trecondi 1 g powder for solution for infusion.

One vial contains 1 g of treosulfan.

Trecondi 5 g powder for solution for infusion.

One vial contains 5 g of treosulfan.
When reconstituted according to Section 4.2, 1 mL of the solution for infusion contains 50 mg treosulfan.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Powder for solution for infusion.
White crystalline powder.

4 Clinical Particulars

4.1 Therapeutic Indications

Adults with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS).

Trecondi (treosulfan) is indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult patients with AML or MDS at increased risk for standard conditioning therapies.

Paediatric patients aged 1 month and older with malignant and non-malignant haematological diseases.

Trecondi (treosulfan) is indicated in combination with fludarabine, with or without thiotepa, as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in paediatric patients older than one month with malignant and non-malignant diseases.

4.2 Dose and Method of Administration

Administration of treosulfan should be supervised by a physician experienced in conditioning treatment followed by alloHSCT.

Dosage.

Adults with AML or MDS.

Treosulfan is given in combination with fludarabine.
The recommended dose and schedule of administration is:
Treosulfan 10 g/m² body surface area (BSA) per day as a two-hour intravenous infusion, given on three consecutive days (day -4, -3, -2) before stem cell infusion (day 0). The total treosulfan dose is 30 g/m²;
Fludarabine 30 mg/m² BSA per day as a 0.5-hour intravenous infusion, given on five consecutive days (day -6, -5, -4, -3, -2) before stem cell infusion (day 0). The total fludarabine dose is 150 mg/m²;
Treosulfan should be administered before fludarabine on days -4, -3, -2 (FT₁₀ regimen).

Dosage adjustment.

Elderly.

No dose adjustment is necessary in any subset of the elderly population.

Renal and hepatic impairment.

No dose adjustment is necessary for mild or moderate impairment, but treosulfan is contraindicated in patients with severe impairment (see Section 4.3).

Paediatric population aged 1 month and older with malignant and non-malignant haematological diseases.

Treosulfan is given in combination with fludarabine, with thiotepa (intensified regimen; FT_10-14TT regimen) or without thiotepa (FT_10-14 regimen).
The recommended dose and schedule of administration is:
Treosulfan 10-14 g/m² body surface area (BSA) per day as a two-hour intravenous infusion, given on three consecutive days (day -6, -5, -4) before stem cell infusion (day 0). The total treosulfan dose is 30-42 g/m²;
The dose of treosulfan should be adapted to the patient's BSA as follows (see Section 5.2) (see Table 1):

Fludarabine 30 mg/m² BSA per day as a 0.5-hour intravenous infusion, given on five consecutive days (day -7, -6, -5, -4, -3) before stem cell infusion (day 0). The total fludarabine dose is 150 mg/m²;
Treosulfan should be administered before fludarabine;
Thiotepa (intensified regimen 5 mg/kg twice a day), given as two intravenous infusions over 2-4 hours on day -2 before stem cell infusion (day 0).
The safety and efficacy of treosulfan in children less than 1 month of age has not yet been established.

Method of administration.

Treosulfan is for intravenous use as a two-hour infusion.

Precautions to be taken before handling or administering the medicinal product.

When handling treosulfan, inhalation, skin contact or contact with mucous membranes should be avoided. Pregnant personnel should be excluded from handling cytotoxics.
Intravenous administration should be performed using a safe technique to avoid extravasation (see Section 4.4).

Instructions on reconstitution of the medicine before administration.

As with all cytotoxic substances, appropriate precautions should be taken when handling treosulfan.
Trained personnel should reconstitute the medicinal product. When handling treosulfan, inhalation, skin contact or contact with mucous membranes should be avoided (the use of adequate protective disposable gloves, goggles, gown and mask is recommended). Contaminated body parts should be carefully rinsed with water and soap, the eyes should be rinsed with sodium chloride 9 mg/mL (0.9%) solution. If possible it is recommended to work on a special safety workbench, equipped with laminar flow, with liquid-impermeable, absorbent disposable foil. Adequate care and precautions should be taken in the disposal of items (syringes, needles, etc.) used to reconstitute cytotoxic medicinal products. Use Luer-lock fittings on all syringes and sets. Large bore needles are recommended to minimise pressure and the possible formation of aerosols. The latter may also be reduced by the use of a venting needle.
Pregnant personnel should be excluded from handling cytotoxics.
Instructions for reconstitution of treosulfan:
1. Treosulfan is reconstituted in its original glass container. Reconstituted solutions of treosulfan may be combined into a larger glass vial, EVA bag or PE bag. Do not dilute reconstituted product.
2. To avoid solubility problems, warm the solvent, sodium chloride 4.5 mg/mL (0.45%) solution, to 25°C - 30°C (not higher), for example by using a water bath.
3. Remove the treosulfan powder carefully from the inner surface of the vial by shaking. This procedure is very important, because moistening of powder that sticks to the surface results in caking. If this happens, vigorously shake the vial to redissolve the cake.
4. Reconstitute each vial of Trecondi containing 1 g treosulfan in 20 mL of pre-warmed (maximum 30°C) sodium chloride 4.5 mg/mL (0.45%) solution by shaking.
Reconstitute each vial of Trecondi containing 5 g treosulfan in 100 mL of pre-warmed (maximum 30°C) sodium chloride 4.5 mg/mL (0.45%) solution by shaking.
For preparation of sodium chloride 4.5 mg/mL (0.45%) solution equivalent volumes of sodium chloride 9 mg/mL (0.9%) solution and water for injections can be mixed.
The reconstituted solution contains 50 mg treosulfan per mL and appears as a clear colourless solution. Solutions showing any sign of precipitation should not be used.

4.3 Contraindications

Hypersensitivity to the active substance.
Active non-controlled infectious disease.
Severe concomitant cardiac, lung, liver, and renal impairment.
Fanconi anaemia and other DNA breakage repair disorders.
Pregnancy and lactation (see Section 4.6 Fertility, Pregnancy and Lactation).
Administration of live vaccine.

4.4 Special Warnings and Precautions for Use

Myelosuppression.

Profound myelosuppression with pancytopenia is the desired therapeutic effect of treosulfan-based conditioning treatment, occurring in all patients. It is therefore recommended to monitor blood cell counts frequently until recovery of the haematopoietic system.
During phases of severe neutropenia (median duration of neutropenic period is 14-17.5 days in adults and 20-22 days in paediatric patients) the risk of infection is increased. Prophylactic or empiric anti-infective treatment (bacterial, viral, fungal) should therefore be considered. Growth factors (G-CSF, GM-CSF), platelet and/or red blood cell support should be given as indicated.

Secondary malignancies.

Secondary malignancies are well-established complications in long-term survivors after alloHSCT. How much treosulfan contributes to their occurrence is unknown. The possible risk of a second malignancy should be explained to the patient. On the basis of human data, treosulfan has been classified by the International Agency for Research on Cancer (IARC) as a human carcinogen.

Mucositis.

Oral mucositis (including high-grade severity) is a very common undesirable effect of treosulfan-based conditioning followed by alloHSCT (see Section 4.8). Use of mucositis prophylaxis (e.g. topical antimicrobials, barrier protectants, ice and adequate oral hygiene) is recommended.

Vaccines.

Concomitant use of live attenuated vaccines is not recommended.

Embryofetal toxicity and contraception.

Treosulfan can impair fertility (see Section 4.6 Fertility, Pregnancy and Lactation).
Ovarian suppression and amenorrhoea with menopausal symptoms commonly occur in pre-menopausal patients (see Section 4.6 Fertility, Pregnancy and Lactation).
Pregnant women should be informed of the potential risk to a fetus (see Section 4.6 Fertility, Pregnancy and Lactation). Females of reproductive potential should be advised to have a pregnancy test within 7 days prior to starting treatment with Trecondi and to use effective contraception during treatment and for at least 6 months after stopping treatment.
Males with female partners of reproductive potential should be advised to use effective contraception during treatment and for at least 6 months after the last dose of Trecondi.

Use in the elderly.

No data available.

Paediatric use.

Seizures.

There have been isolated reports of seizures in infants (≤ 4 months of age) with primary immunodeficiencies after conditioning treatment with treosulfan in combination with fludarabine or cyclophosphamide. Therefore, infants ≤ 4 months of age should be monitored for signs of neurological adverse reactions. Although it cannot be proved that treosulfan was the cause, the use of clonazepam prophylaxis for children younger than 1 year might be considered.

Respiratory, thoracic and mediastinal disorders.

There was a significant association between age and respiratory toxicity in paediatric patients treated with treosulfan-based conditioning.
Children younger than one year (mainly non-malignant diseases, especially immunodeficiencies) experienced more respiratory grade III/IV toxicity, possibly due to pulmonary infections already existing before the start of conditioning treatment.

Skin disorders.

An increase of skin disorders (e.g. rash, dermatitis) was observed when patients received sodium bicarbonate-containing hydration in the course of treosulfan infusion, potentially because of acceleration of the pH-dependent formation of alkylating epoxides.
Diaper dermatitis may occur in small children because of excretion of treosulfan in the urine. Therefore, nappies should be changed frequently up to 6-8 hours after each infusion of treosulfan.
Keep skin clean and dry on days of treosulfan infusion.

Effects on laboratory tests.

No data available.

Extravasation.

Treosulfan is considered an irritant. Intravenous application should be performed using a safe technique. If extravasation is suspected, general safety measures should be implemented. No specific measure has been proven to be recommendable.

4.5 Interactions with Other Medicines and Other Forms of Interactions

No interaction of treosulfan was observed in high-dose chemotherapy.
Detailed in vitro studies did not completely exclude potential interactions between high plasma concentrations of treosulfan and CYP3A4, CYP2C19, or P-gp substrates. Physiologically-based pharmacokinetic modelling predicted a weak (AUC ratio ≥ 1.25 and < 2) to moderate (AUC ratio ≥ 2 and < 5) interaction for CYP3A4, a weak interaction for CYP2C19, and a negligible (AUC ratio < 1.25) interaction for P-glycoprotein (P-gp). Therefore, medicinal products with a narrow therapeutic index (e.g. digoxin) that are substrates for CYP3A4, CYP2C19 or P-gp should not be given during treatment with treosulfan.
Considering overall timing of treatments and the respective pharmacokinetic properties of concomitantly used drugs (e.g. half-life), the interaction potential can be reduced to "no interaction" (AUC ratio < 1.25), if all concomitantly used drugs are dosed 2 h before or 8 h after the 2 h intravenous infusion of treosulfan.
In in vitro studies treosulfan did not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 using testosterone as substrate. However, using midazolam as the substrate, treosulfan was a reversible inhibitor for CYP2C19 and 3A4. Treosulfan did not inhibit substrate transport via various transport proteins with the exception of P-glycoprotein (P-gp) and MATE2 at very high concentrations.
The effect of treosulfan on the pharmacokinetics of fludarabine and thiotepa is not known.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

In common with other alkylating conditioning agents, treosulfan may impair fertility in men and women.
Males of reproductive potential should seek advice on cryo-conservation of sperm prior to treatment with Trecondi because of the possibility of irreversible infertility due to therapy with treosulfan. Treosulfan can cause ovarian suppression and amenorrhoea with menopausal symptoms in premenopausal women.
Because of the potential risk to the fetus, both sexually active men and women of childbearing potential have to use effective contraception during and up to 6 months after treatment (see 'Use in pregnancy').
Specific reproductive toxicity studies with treosulfan in animals were not conducted. However, during chronic oral toxicity tests in rats, spermatogenesis and ovarian function were significantly affected. Data on impairment of fertility from the published literature includes reports of impaired spermatogenesis and uterine-ovarian and sperm development, and permanent reduction of reserve primordial ovarian follicles mice and rats treated with treosulfan or its active moieties.
(Category D)
There are no adequate or well-controlled studies with Trecondi in pregnant women.
Animal studies are insufficient with respect to developmental toxicity. Based on the cytotoxicity and genotoxicity of treosulfan and its active moieties, a potential for fetal toxicity and teratogenicity exists. Trecondi is contraindicated during pregnancy (see Section 4.3 Contraindications).
It is unknown whether treosulfan or its active moieties are excreted in human milk. No adequate or well-controlled studies have been conducted to assess the impact of Trecondi on milk production or its presence in breast milk. Since many drugs are excreted in human milk and because of the potential for serious adverse reactions in breastfeeding infants due to Trecondi, a risk to breast-fed children cannot be excluded. Breastfeeding should be discontinued during treatment with Trecondi and for at least 6 months after the last dose.

4.7 Effects on Ability to Drive and Use Machines

Treosulfan has moderate influence on the ability to drive and use machines. It is likely that certain adverse reactions of treosulfan like nausea, vomiting or dizziness could affect these functions.

4.8 Adverse Effects (Undesirable Effects)

Summary of the safety profile.

Profound myelosuppression/pancytopenia is the desired therapeutic effect of conditioning therapy and occurs in all patients. Blood cell counts usually recover after HSCT.
The most commonly observed adverse reactions (adults/ paediatric patients) after treosulfan-based conditioning followed by alloHSCT include infections (12.9% /12.2%), gastrointestinal disorders (nausea [38.5%/27.8%], stomatitis [36.4%/67.0%], vomiting [22.5%/41.7%], diarrhoea [15.2%/34.8%], abdominal pain [10.6%/18.3%]), fatigue (14.8%/1.7%), hepatotoxicity [0.3%/26.1%], febrile neutropenia (10.9%/0.9%), decreased appetite [8.2%/0.9%], maculopapular rash (6.4%/7.8%), pyrexia [5.5%/13.0], headache [5.2%/2.6%], oedema (7.3%/0%), and increases of alanine transaminase (ALT [5.5%/11.3%]), aspartate transaminase (AST [4.9%/7.8%]) and bilirubin (17.9%/7.0%).

Adults.

Tabulated list of adverse reactions. The frequencies of adverse reactions reported in the table below are derived from 5 clinical trials (including a total of 613 patients) where treosulfan combined with fludarabine was investigated as conditioning treatment prior to alloHSCT in adult patients. Treosulfan was administered in a dose range of 10-14 g/m² BSA on 3 consecutive days.
Adverse reactions are listed below, by system organ class and by frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each frequency group, undesirable effects are presented in order of decreasing seriousness. (See Table 2.)

Description of selected adverse reactions.

Infections.

The overall incidence of infections was 12.9% (79/613). The most frequent type was lung infection (12/79 [15.2%]). Pathogens included bacteria (e.g. Staphylococcus, Enterococcus, Corynebacterium), viruses (e.g. cytomegalovirus [CMV], Epstein-Barr virus [EBV], herpes) as well as fungi (e.g. candida). The infection rate was lowest in patients treated with the dose regimen of 10 g/m² of treosulfan per day, from day -4 to -2 (8.1%).

Neoplasms benign, malignant and unspecified (including cysts and polyps).

One of 613 adult patients (0.2%) developed a second malignancy (breast cancer). A few further cases of second malignancies after treosulfan-based conditioning have been reported by other investigators. After long-term therapy with conventional doses of oral treosulfan in patients with solid tumours acute myeloid leukaemia was observed in 1.4% of 553 patients.

Blood and lymphatic system disorders.

Blood disorders were observed in 70 of 613 adult patients (11.4%). The most frequent adverse reaction was febrile neutropenia (10.9%). The lowest incidence was noted with the dose regimen of 10 g/m²/day, day -4 to -2 (4.4%).
The median (25%/75% percentiles) duration of neutropenia was 14 (12, 20) days with the 10 g/m²; treosulfan dose and 17.5 (14, 21) days with the 14 g/m² treosulfan dose.

Cardiac disorders.

Cardiac disorders were observed in 26 patients (4.2%). The most frequent adverse reactions were cardiac arrhythmias, e.g. atrial fibrillation (1.1%), sinus tachycardia (1.0%), pericardial effusion (0.3%), supraventricular tachycardia (0.3%), and ventricular extrasystole (0.3%). Isolated cases of cardiac arrest, cardiac failure, and myocardial infarction occurred. The lowest frequency of cardiac disorders was seen with the dose regimen of 10 g/m²/day, day -4 to -2 (2.6%).

Gastrointestinal disorders.

Gastrointestinal disorders were observed in 383 patients (62.5%). The most frequent adverse reactions reported were nausea (38.5%), stomatitis (36.4%), vomiting (22.5%), diarrhoea (15.2%), and abdominal pain (10.6%). The lowest frequencies of these adverse reactions were seen with the dose regimen of 10 g/m² per day, day -4 to -2 ((21.5%, 32.2%, 14.8%, 5.9%, and 6.7% respectively).

Hepatobiliary disorders.

The overall incidence of veno-occlusive liver disease (VOD) was 0.8% (5/613). VOD occurred only with the dose regimen of 14 g/m²/day treosulfan. None of these cases were fatal or life-threatening.

Paediatric population.

Tabulated list of adverse reactions. The adverse reactions reported in the table below are derived from two clinical trials (including a total of 115 patients; median age 7 years [range 0-17 years]) where treosulfan combined with fludarabine (and mostly with additional thiotepa) was administered as conditioning treatment prior to alloHSCT in paediatric patients with malignant or non-malignant diseases. Treosulfan was administered in a dose range of 10-14 g/m² BSA on three consecutive days.
Adverse reactions are listed below, by system organ class and by frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each frequency group, undesirable effects are presented in order of decreasing seriousness. (See Table 3.)

Description of selected adverse reactions.

Infections.

The overall incidence of infections in 115 paediatric patients was 12.2% (14/115) and thus comparable to that seen in adults. The frequency was higher in the paediatric age group 12-17 years (6/39 [15.4%]) compared to younger children (8/76 [10.5%]).

Neoplasms benign, malignant and unspecified (including cysts and polyps).

One case of a second malignancy (myelodysplastic syndrome) was reported in a child about 12 months after treosulfan-based conditioning for sickle cell disease.
Five cases of a second malignancy (myelodysplastic syndrome, acute lymphoblastic leukaemia, Ewing's sarcoma) were reported by other investigators after treosulfan-based conditioning. All five paediatric patients received alloHSCT for primary immunodeficiencies, i.e. diseases with an increased risk for neoplasias per se.

Blood and lymphatic system disorders.

The median (25%/75% percentiles) duration of neutropenia was 22 (17, 26) days in paediatric patients with malignant diseases and 20 (16, 26) days in patients with non-malignant disorders.

Nervous system disorders.

Seizure in the context of an encephalitis infection was reported in one of 115 paediatric patients. A report from an investigator-initiated trial performed in children with primary immunodeficiencies lists four cases of seizures occurring after other treosulfan-based conditioning regimens (see Section 4.4).

Reporting of suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

The principal toxic effect of treosulfan is profound myeloablation and pancytopenia. In addition, acidosis, skin toxicity, nausea, vomiting and gastritis may occur. In the absence of haematopoietic stem cell transplantation, the recommended dose of treosulfan would constitute an overdose. No specific antidote of treosulfan overdose is known. The haematologic status should be closely monitored and vigorous supportive measures instituted as medically indicated.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, ATC code: L01AB02.

Mechanism of action.

Treosulfan is a prodrug of a bifunctional alkylating agent with cytotoxic activity to haematopoietic precursor cells. The activity of treosulfan is due to the spontaneous conversion into a mono-epoxide intermediate and L-diepoxybutane (see Section 5.2).
The epoxides formed alkylate nucleophilic centres of deoxyribonucleic acid (DNA) and are able to induce DNA cross-links which are considered responsible for the stem cell depleting and antineoplastic effects.

Pharmacodynamic effects.

Treosulfan has a broad antineoplastic and antileukaemic activity. This was demonstrated against transplanted mouse and rat lymphomas/leukaemias, sarcomas and hepatomas, human tumour xenografts, human tumour biopsies and cell lines.
The immunosuppressive effects of treosulfan are attributed to its toxicity against primitive and committed progenitor cells, T and NK cells, reduction of cellularity of primary and secondary lymphatic organs and a preclusive effect on the 'cytokine storm' that precedes the development of Graft-versus-Host-Disease (GvHD) and is involved in the pathogenesis of veno-occlusive disease.

Clinical trials.

In the pivotal phase III trial, adult patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and increased risk for standard conditioning therapies because of higher age (≥ 50 years) or comorbidities (haematopoietic cell transplantation comorbidity index [HCT-CI] score > 2) were randomised to receive a conditioning regimen with 3 x 10 g/m² treosulfan combined with fludarabine (FT₁₀; n = 268) or a regimen of intravenous busulfan (total dose 6.4 mg/kg) combined with fludarabine (FB2; n = 283), followed by alloHSCT. 64% of patients had AML and 36% MDS. The median age of patients was 60 years (range 31-70 years); 25% of patients were older than 65 years.
The primary endpoint of this study was event-free survival (EFS) after 2 years. Events were defined as relapse of disease, graft failure or death (whatever occurred first). Non-inferiority of FT₁₀ versus the reference FB2 was statistically proven (Figure 1).

Analyses of EFS at 2 years for various pre-defined subgroups (donor type, risk group, disease, age group, HCT-CI score, remission status at study entry, and various combinations of these parameters) were always in favour of the treosulfan regimen (hazard ratio [HR] of FT₁₀ vs. FB2 < 1), with only one exception (risk group II of matched related donor [MRD] patients; HR 1.18 [95% CI 0.61, 2.26]).
Further results are shown in Table 4.

Results of GvHD are shown in Table 5.

Paediatric population.

The efficacy and safety of treosulfan-based conditioning was evaluated in 70 patients with acute lymphoblastic leukaemia (ALL), AML, MDS, or juvenile myelomonocytic leukaemia (JMML) who received a conditioning regimen with treosulfan and fludarabine with (n = 65) or without (n = 5) thiotepa (see Section 4.2). A total of 37 patients (52.9%) were younger than 12 years.
No patient experienced a primary graft failure but one patient with ALL experienced a secondary graft failure. The incidence of complete donor-type chimerism was 94.2% (90% CI 87.2-98.0%) at day +28 visit, 91.3% (90% CI 83.6-96.1%) at day +100 visit and 91.2% (90% CI 82.4-96.5%) at month 12 visit.
The overall survival at 24 months is 85.7% (90% CI 77.1-91.2%). A total of 12 of the 70 patients (17.1%) died, 8 patients because of relapse/progression and 4 patients transplant-related. The freedom from transplant-related mortality until day +100 after HSCT (primary endpoint) is 98.6% (90% CI 93.4-99.9%) because one of the 70 patients died due to transplantation/treatment-related cause until day +100 after HSCT. Transplant-related mortality at 24 months is 4.6% (90% CI 1.8 - 11.4%). Sixteen patients had a relapse/progression. The cumulative incidence of relapse/progression is 23.0% (90% CI 14.7-31.3%) at month +24.
The efficacy and safety of treosulfan/fludarabine ± thiotepa-based conditioning was further evaluated in 51 patients with non-malignant diseases (primary immunodeficiency, haemoglobinopathy, inborn error of metabolism and bone marrow failure syndromes). Treosulfan dose was adapted to the patient's BSA and 10, 12, or 14 g/m² body surface area per day was administered as a two-hour intravenous infusion on day -6, -5, and -4 prior to stem cell infusion (day 0). Fifty evaluable patients treated with the reference conditioning regimen busulfan/fludarabine ± thiotepa served as active control group. Busulfan dose was adapted to the patient's body weight and 3.2 to 4.8 mg/kg/day were administered on days 7, 6, 5, and 4.
Most trial subjects (84% in both arms) received the intensified regimen with thiotepa given in 2 single doses of 5 mg/kg/body weight on day -2. Most patients were 28 days to 11 years of age (88.2% in the treosulfan arm and 80% in the busulfan arm).
The incidence of freedom from transplantation (treatment) related mortality until day +100 (primary endpoint) was 100.0% (90% CI 94.3%-100.0%) in the treosulfan arm and 90.0% (90% CI 80.1%96.0%) in the busulfan arm. Overall survival at 1 year was 96.1% (90% CI 88.0%-98.8%) with treosulfan and 88.0% with busulfan (90% CI 77.9%-93.7%); HR 0.29 (90% CI 0.08-1.09).

5.2 Pharmacokinetic Properties

Treosulfan is a prodrug that is spontaneously converted under physiological conditions (pH 7.4; 37°C) into a monoepoxide intermediate and L-diepoxybutane with a half-life of 2.2 hours.

Absorption.

After intravenous administration, peak plasma levels are reached at the end of the infusion time. Maximum plasma levels (mean ± SD) in adult patients after a 2-hour intravenous infusion of 10, 12, or 14 g/m² treosulfan were 306 ± 94 microgram/mL, 461 ± 102 microgram/mL, and 494 ± 126 microgram/mL, respectively.

Distribution.

Treosulfan is rapidly distributed in the body. A very low penetration of blood-brain-barrier by treosulfan was observed in rats. The treosulfan concentrations in brain tissue were 95%-98% lower than in plasma. However, an approximately 3-fold higher exposure in brain tissue of juvenile rats in comparison to young adults was found. The volume of distribution in adult patients is about 20-30 litres. No dose accumulation with the recommended daily treatment on three consecutive days was observed. Treosulfan does not bind to plasma proteins.

Metabolism.

Under physiological conditions (pH 7.4, temperature 37°C), the pharmacologically inactive treosulfan is converted spontaneously (non-enzymatically) into the active monoepoxide intermediate (S,S-EBDM = (2S,3S)-1,2-epoxybutane-3,4-diol-4-methanesulfonate) and finally to L-diepoxibutane (S,S-DEB = (2S,3S)-1,2:3,4-diepoxybutane).
In vitro data indicates that treosulfan is weakly metabolised by CYP2D6.

Excretion.

Plasma concentrations of treosulfan decline exponentially and are best described by a first order elimination process fitted by a two-compartment model.
The terminal half-life (T_1/2ß) of intravenously administered treosulfan (up to 47 g/m²) is approximately 2 hours. Approximately 25-40% of the treosulfan dose is excreted unchanged with the urine within 24 hours, nearly 90% of which within the first 6 hours after administration.

Linearity/non-linearity.

Regression analysis of the area under the curve (AUC_0-∞) versus treosulfan dose indicated a linear correlation.

Renal and hepatic impairment.

No pharmacokinetic studies with treosulfan were done in patients with severe renal or hepatic impairment, because such patients are generally excluded from alloHSCT. About 25-40% of treosulfan is excreted in urine; however, an influence of renal function on renal clearance of treosulfan was not observed.

Paediatric population.

Conventional dose calculation simply based on BSA results in a significantly higher exposure (AUC) of smaller children and infants with low BSA compared to adolescents or adults. Therefore, dosing of treosulfan in paediatric patients has to be adapted to the BSA (see Section 4.2).
Mean apparent terminal half-life of treosulfan was comparable between the different age groups and ranged between 1.3 and 1.6 hours.

5.3 Preclinical Safety Data

Genotoxicity.

Due to its alkylating mechanism of action treosulfan is characterised as a genotoxic compound with carcinogenic potential. Reports from the published literature indicated that treosulfan and its active moieties were mutagenic in bacterial and mammalian assays and clastogenic in vitro and in vivo.

Carcinogenicity.

Due to its alkylating mechanism of action treosulfan is characterised as a genotoxic compound with carcinogenic potential. Treosulfan has been classified by the International Agency for Research on Cancer (IARC) as a human carcinogen.

6 Pharmaceutical Particulars

6.1 List of Excipients

None.

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf Life

Unopened vial.

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

Reconstituted solution for infusion.

After reconstitution with sodium chloride 4.5 mg/mL (0.45%) solution, chemical and physical stability has been demonstrated for 1 day (24 hours) at 25°C.
From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.
Do not store in a refrigerator (2°C-8°C) as this might cause precipitation.

6.4 Special Precautions for Storage

Store below 25°C.
For storage conditions after reconstitution of the medicinal product, see Section 6.3.

6.5 Nature and Contents of Container

Trecondi 1 g powder for solution for infusion.

Colourless type I glass vial, with rubber stopper and aluminium cap containing 1 g of treosulfan.

Trecondi 5 g powder for solution for infusion.

Colourless type I glass vial, with rubber stopper and aluminium cap containing 5 g of treosulfan.
Trecondi is available in packs of 1 or 5 vials.
Not all pack sizes may be marketed.

6.6 Special Precautions for Disposal

As with all cytotoxic substances, appropriate precautions should be taken when handling treosulfan (see Section 4.2).
Treosulfan has mutagenic and carcinogenic potential. Remnants of the medicinal product as well as all materials that have been used for reconstitution and administration must be destroyed according to standard procedures applicable to antineoplastic agents.
In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical structure.

CAS number.

299-75-2.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Service Unavailable

Consumer medicine information

Trecondi

Treosulfan

Keep track of your medicines

BRAND INFORMATION